At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03378 HANXBIO-B
Closed 05-22 16:08:21
28.520
+0.040
+0.14%
High29.580Low27.800Vol63.00K
Open29.100D1 Closing28.480Amplitude6.25%
Mkt Cap3.85BTradable Cap3.85BTotal Shares135.00M
T/O1.78MT/O Rate0.05%Tradable Shares135.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Hanx Biopharma files HKEX return disclosing share repurchase at HKD 28.58 each
Reuters  ·  20:10
Hanx Biopharma files HKEX return disclosing share repurchase at HKD 28.58 each
HANXBIO-B (03378) Spends Approximately HK$674,700 on Share Buyback on May 21
Stock News  ·  05-21 21:28
HANXBIO-B (03378) Spends Approximately HK$674,700 on Share Buyback on May 21
HANXBIO-B adds 23,100 treasury shares through on-market buyback, cumulative repurchase reaches 0.56% of share capital
Bulletin Express  ·  05-21 21:23
HANXBIO-B adds 23,100 treasury shares through on-market buyback, cumulative repurchase reaches 0.56% of share capital
Hanx Biopharmaceuticals Adds 26,000 H-Shares to Treasury; Outstanding Share Count Dips 0.02%
Bulletin Express  ·  05-20 19:03
Hanx Biopharmaceuticals Adds 26,000 H-Shares to Treasury; Outstanding Share Count Dips 0.02%
HANXBIO-B (03378) Repurchases 26,000 Shares for HK$766,200 on May 20
Stock News  ·  05-20 18:56
HANXBIO-B (03378) Repurchases 26,000 Shares for HK$766,200 on May 20
Hanx Biopharma files HKEX next-day return, discloses buyback at HKD 29.47/share
Reuters  ·  05-20 18:49
Hanx Biopharma files HKEX next-day return, discloses buyback at HKD 29.47/share
HANXBIO-B Buys Back 26,500 H-Shares; Treasury Stock Climbs to 709,000
Bulletin Express  ·  05-19
HANXBIO-B Buys Back 26,500 H-Shares; Treasury Stock Climbs to 709,000
With Lock-up Expiry Approaching, Can HANXBIO-B (03378) Maintain the Breakeven Level for Cornerstone Investors?
Stock News  ·  05-19
With Lock-up Expiry Approaching, Can HANXBIO-B (03378) Maintain the Breakeven Level for Cornerstone Investors?
HANXBIO-B (03378) Spends HK$782,100 on Share Buyback on May 18
Stock News  ·  05-18
HANXBIO-B (03378) Spends HK$782,100 on Share Buyback on May 18
Hanx Biopharma files HKEX return disclosing share repurchase at HKD 29.63
Reuters  ·  05-18
Hanx Biopharma files HKEX return disclosing share repurchase at HKD 29.63
Hanx Biopharmaceuticals files HKEX return disclosing share buyback at HKD 29.1 each
Reuters  ·  05-15
Hanx Biopharmaceuticals files HKEX return disclosing share buyback at HKD 29.1 each
HANXBIO-B repurchases 27,800 H shares for HKD 0.84 million; outstanding float trimmed by 0.02%
Bulletin Express  ·  05-14
HANXBIO-B repurchases 27,800 H shares for HKD 0.84 million; outstanding float trimmed by 0.02%
HANXBIO-B (03378) Spends Approximately HK$838,500 on Share Buyback of 27,800 Shares on May 14
Stock News  ·  05-14
HANXBIO-B (03378) Spends Approximately HK$838,500 on Share Buyback of 27,800 Shares on May 14
Hanx Biopharmaceuticals repurchases HKD 0.82 million in H shares, boosting treasury stock to 598,600 units
Bulletin Express  ·  05-13
Hanx Biopharmaceuticals repurchases HKD 0.82 million in H shares, boosting treasury stock to 598,600 units
Hanx Biopharmaceuticals files HKEX next-day return, discloses buyback at HKD 30.98/share
Reuters  ·  05-13
Hanx Biopharmaceuticals files HKEX next-day return, discloses buyback at HKD 30.98/share
HANXBIO-B (03378) Spends HK$817,950 on Share Repurchase of 26,400 Shares on May 13
Stock News  ·  05-13
HANXBIO-B (03378) Spends HK$817,950 on Share Repurchase of 26,400 Shares on May 13
Hanx Bio repurchases 24,900 H shares; treasury holdings rise to 572,200
Bulletin Express  ·  05-12
Hanx Bio repurchases 24,900 H shares; treasury holdings rise to 572,200
HANXBIO-B Spends HK$792,500 on Share Buyback on May 12
Stock News  ·  05-12
HANXBIO-B Spends HK$792,500 on Share Buyback on May 12
HANXBIO-B Buys Back 22,600 H Shares at Average HK$32.09; Treasury Stock Reaches 547,300 Shares
Bulletin Express  ·  05-11
HANXBIO-B Buys Back 22,600 H Shares at Average HK$32.09; Treasury Stock Reaches 547,300 Shares
HANXBIO-B (03378) Spends HK$725,000 on Share Buyback of 22,600 Shares on May 11
Stock News  ·  05-11
HANXBIO-B (03378) Spends HK$725,000 on Share Buyback of 22,600 Shares on May 11
No data available

Introduction

Company Name.
HANXBIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a China-based company mainly engaged in the research and development of immune-oncology therapies. The Company’s product pipeline comprises clinical stage drug candidates focused on oncology and preclinical stage drug candidates, including Core Product HX009 and Key Products HX301 and HX044, as well as antibody drug conjugate, bispecific antibody and monoclonal antibody for both autoimmune and oncology market. HX009 is a bifunctional anti-programmed cell death protein 1 (PD-1) antibody signal regulatory protein α (SIRPα) fusion protein developed in-house. HX301 is a multi-targeted kinase inhibitor targeting critical pathways such as colony-stimulating factor-1 receptor (CSF1R), AMPK-associated protein kinase 5 (ARK5), FMS-like tyrosine kinase 3 (FLT-3), and cell cycle-independent kinase 4/6 (CDK 4/6). HX044 is a novel bifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody SIRPα fusion protein.
Issue price:
--